Pluri Inc. · NASDAQ:PLUR
Pluri — Investor Presentation (April 2026)
20 slides from Pluri's investor presentation, April 2026
Slide 1: Where Technology Comes to Life
WHERE TECHNOLOGY COMES TO LIFE Q2 2026
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements within the Israeli Securities Law, 1968, the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws, as amended, regarding Pluri Inc. and/or its subsidiaries (collectively the “Company” o
Slide 3: Pluri Venture Creation
Pluri Venture Creation Company Sectors Partners ~$14 million (as of December 31, 2025) Regenerative Medicine and wellness > Cultivated Meat Cell-Based Agriculture
Slide 4: Eight Billion Lives. One Planet. Zero Time to Waste.
Eight Billion Lives. One Planet. Zero Time to Waste. Aging and Health Climate Change Food Security Sustainability A growing, aging world urgently needs scalable, sustainable solutions
Slide 5: Single Platform, Multiple Opportunities
Single Platform, Multiple Opportunities Human health and Longevity Placental cell therapy Cultivated coffee 100% ownership Injectable placental cell-based therapy designed to reduce inflammation and promote tissue healing Cultivated cacao 79% ownership Longevity Immunotherapy Osteoarthritis - Full f
Slide 6: Pluri Technological Platform
Pluri Technological Platform Innovative Validated
Slide 7: Pluri Technological Platform: Bio-Farming
Pluri Technological Platform Bio-Farming: Industrial Scale Production Advantages PluriMatrix
Slide 8: Health and Wellbeing: Supporting Longevity and the Aging Process
Health and Wellbeing: Supporting Longevity and the Aging Process
Slide 9: Longevity and the Aging Process: Physical Deterioration Over Time
Longevity and the Aging Process: Physical Deterioration Over Time WHO
Slide 10: One Platform. Multiple Products.
One Platform. Multiple Products. PLX Cells PLX Exosomes & Plant Extracellular • Regenerative skin support, Antioxidant protection, Anti-inflammatory action, Wound- Vesicles healing support, Collagen-boosting ("Dermatologically tested", "Clinically tested", "Safe for skin", "Kind to skin", "Dermatolo
Slide 11: Stem Cell Use Authorization in the US
Stem Cell Use Authorization in the US Premium Aesthetics Solutions Florida law (SB 1768 / HB 1617) passed on July,2025
Slide 12: Revolutionizing Beauty and Wellness Through Cell Science
Revolutionizing Beauty and Wellness Through Cell Science Market Science-Driven Opportunity Innovation $200B From Therapy to Partnership & Lifestyle Growth Ingredients: • • •
Slide 13: Foodtech Partnership that Becomes Independence
Foodtech Partnership that Becomes Independence: a Proven Path to Value Creation Pluri holds majority ownership in all companies in which it is a partner
Slide 14: Growing the Future of Food with Cultivated Meat
Growing the Future of Food with Cultivated Meat Ever After Foods leverages Pluri’s cell expansion technology to produce mass scale, cost-effective food products in an efficient and sustainable manner, aiming to solve the industry’s scalability challenges Environmental Ethical Consumer ● Less land an
Slide 15: Ever After Foods Milestones
Ever After Foods Milestones Expected completion of manufacturing system development, initiation of regulatory processes, and receipt of initial regulatory approvals in selected markets Granted exclusive global royalty-bearing license to use its IP and expertise I $7.5 million according to a $40 mill
Slide 16: Reimagining Coffee & Cacao Without Ecological Cost
Reimagining Coffee & Cacao Without Ecological Cost Unstable supply Rising prices Drying risen Roasting Complex supply chain $11,000 Brewing Inconsistent quality
Slide 17: Milestones
Milestones ‘Oo Jan. May Sep. H2 2026 @ 2024 2024 2024 2025 7) o © ® ® @ @ 5 Internal POC Company creation, Product POC deals with Completion of product POC with rs) (funded by Pluri) CEO and team prototype global partners the Japanese partner recruitment nee Progress to Regulatory o° submissions in
Slide 18: Our Collaborative Network of Partnerships
Our Collaborative Network of Partnerships Regulatory Scientific Collaborations Funding and Partnering
Slide 19: Our Team
Our Team Yaky Yanay Liat Zalts Lior Raviv Dr. Michal Sheleg, PhD Nimrod Bar Zvi CEO & President Chief Financial Officer Chief Technology Officer VP Clinical Development Chief Commercial Officer Dr. Arthur Machlenkin, PhD Nofar Glaich-Dabach Orly Amiran Efrat Kaduri Ori Shalem Chief Scientific Office
Slide 20: Thank You
THANK YOU. Our cell-based innovations are aimed at transforming industries with a goal to create a more sustainable, healthier world. From the food we eat to the medicine we consume, we are building solutions that can potentially serve humanity, one breakthrough at a time. For further info: investor